The polymorphic oxidation of beta-adrenoceptor antagonists

https://doi.org/10.1016/0163-7258(89)90126-5Get rights and content

First page preview

First page preview
Click to open first page preview

References (88)

  • J.H. Riviere et al.

    Inhibition of ethinyloestradiol and tolbutamide metabolism by quinoline derivatives in vitro

    Chem. biol. Interact.

    (1986)
  • R.R. Shah et al.

    Beta-blokers and drug oxidation status

    Lancet

    (1982)
  • L. Shaw et al.

    Irreversible binding and metabolism of propranolol by human liver microsomes—relationship to polymorphic oxidation

    Biochem. Pharmac.

    (1987)
  • G.T. Tucker et al.

    Polymorphic hydroxylation of debrisquine

    Lancet

    (1977)
  • T. Walle et al.

    Stereoselective delivery and actions of beta-receptor antagonists

    Biochem. Pharmac.

    (1988)
  • M. Adams et al.

    In vitro assessment of the mouse as an experimental model for the polymorphic oxidation of metoprolol

    Br. J. Pharmac.

    (1989)
  • S.A.H. Al-Asady et al.

    Covalent binding of propranolol to rat and human liver microsomes: relation to inhibition of lignocaine metabolism

    Br. J. Pharmac.

    (1985)
  • T.R. Bai et al.

    Treatment of hypertension with beta-blocking drugs

    Jl R. Coll. Phys.

    (1982)
  • L. Balant et al.

    Pharmacocinetique de deux medicaments beta-bloquants: detection d'une anomalie pharmacogenetique

    Schweiz. Med. Wochenschr.

    (1976)
  • L. Beeley

    Assessing new drugs

    Practitioner

    (1983)
  • K.O. Borg et al.

    Metabolism of metoprolol-(3H) in man, the dog and the rat

    Acta pharmac. tox.

    (1975)
  • British National Formulary (1987) British Medical Association and The Pharmaceutical Society of Great Britain, London,...
  • D.W.J. Clark et al.

    Adverse effects from metoprolol are not generally associated with oxidation status

    Br. J. clin. Pharmac.

    (1984)
  • C.R. Cleavland et al.

    Effect of route of administration on the relationship between beta-adrenergic blockade and plasma propranolol levels

    Clin. Pharmac. Ther.

    (1972)
  • D.J. Coltart et al.

    Plasma propranolol levels in the qualitative measurement of beta-adrenergic blockade

    Br. Med. J.

    (1970)
  • S.H. Croog et al.

    The effects of antyihypertensive therapy on the quality of life

    N. Engl. J. Med.

    (1986)
  • P. Dayer et al.

    Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers

    Br. J. clin. Pharmac.

    (1982)
  • P. Dayer et al.

    Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents

    Eur. J. clin. Pharmac.

    (1983)
  • P. Dayer et al.

    Consequence pharmacocinetique et clinique du polymorphisme genetique de l'oxydation

    Schweiz. Med. Wochenschr.

    (1983)
  • P. Dayer et al.

    Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol

    Eur. J. clin. Pharmac.

    (1985)
  • P. Dayer et al.

    Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentrations and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol

    Eur. J. clin. Pharmac.

    (1985)
  • P. Dayer et al.

    Stereo- and regioselectivity of hepatic oxidation in man—effect of debrisoquine/sparteine phenotype on bufuralol hydroxylation

    Eur. J. clin. Pharmac.

    (1986)
  • Editorial

    Polymorphic drug oxidation—much ado about nothing?

    Lancet

    (1984)
  • M. Eichelbaum et al.

    The genetic polymorphism of sparteine oxidation

    Xenobiotica

    (1986)
  • D.A.P. Evans et al.

    A family and population study of the genetic polymorphism of debrisoquine in a white British population

    J. med. Genet.

    (1980)
  • J.D. Fitzgerald et al.

    Pharmacology of 4-hydroxypropranolol, a metabolite of propranolol

    Br. J. Pharmac.

    (1971)
  • R.J. Francis et al.

    Determination of bufuraolol and its metabolites in plasma by mass fragmentography and by gas chromatography with electron capture detection

    Biomed. Mass Spectrom.

    (1976)
  • R.J. Francis et al.

    Kinetics and metabolism of (+)-, (-)- and (+/-)-bufuralol

    Eur. J. clin. Pharmac.

    (1982)
  • F.T. Fraunfelder et al.

    Respiratory effects of timolol

    N. Engl. J. Med.

    (1985)
  • S. Freestone et al.

    Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing

    Br. J. Clin. Pharmac.

    (1982)
  • K.-J. Hoffmann et al.

    The effect of impaired renal function on plasma levels and urinary excretion of metoprolol metabolites

    Clin. Pharmacokinet.

    (1980)
  • A.O. Iyun et al.

    Metoprolol and debrisoquine metabolism in Nigerians: lack of evidence for polymorphic oxidation

    Clin. Pharmac. Ther.

    (1986)
  • D.B. Jack et al.

    Lack of evidence for polymorphism in metoprolol metabolism

    Br. J. clin. Pharmac.

    (1983)
  • P.R. Jackson et al.

    Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices

    Br. J. clin. Pharmac.

    (1986)
  • Cited by (23)

    View all citing articles on Scopus
    View full text